Verseau Therapeutics

Verseau is advancing a new class of cancer immunotherapies to stimulate the conversion of immunosuppressive and pro-tumorigenic M2 macrophages into pro-inflammatory M1 macrophages. This transformation, known as macrophage repolarization, induces a synergistic immune response against cancer. Verseau's proprietary human-based discovery engine has identified and validated more than 20 targets for modulating macrophage biology. Our two lead programs targeting PSGL-1 and VSIG4 are rapidly advancing towards clinical trials.